OPEN

Dynamic multidrug recognition by multidrug transcriptional repressor LmrR

Koh Takeuchi^{1,2}, Yuji Tokunaga^{1,3,5}, Misaki Imai³, Hideo Takahashi^{1,4} & Ichio Shimada^{1,5}

SUBJECT AREAS:

SOLUTION-STATE NMR
BIOPHYSICAL CHEMISTRYReceived
8 July 2014Accepted
16 October 2014Published
18 November 2014Correspondence and
requests for materials
should be addressed to
I.S. (shimada@iw-nmr.
f.u-tokyo.ac.jp)

¹Biomedical Information Research Center & Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Aomi 2-3-26, Koto-ku, Tokyo 135-0064, Japan, ²JST, PRESTO, Aomi 2-3-26, Koto-ku, Tokyo 135-0064, Japan, ³Research and Development Department, Japan Biological Informatics Consortium, Tokyo, Japan. Aomi 2-3-26, Koto-ku, Tokyo 135-0064, Japan, ⁴Graduate School of Medical Life Science, Yokohama City University, Kanagawa 230-0045, Japan, ⁵Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

LmrR is a multidrug transcriptional repressor that controls the expression of a major multidrug transporter, LmrCD, in *Lactococcus lactis*. However, the molecular mechanism by which LmrR binds to structurally unrelated compounds and is released from the promoter region remains largely unknown. Here, we structurally and dynamically characterized LmrR in the *apo*, compound-bound and promoter-bound states. The compound-binding site of LmrR exhibits ps–μs dynamics in the *apo* state, and compound ligation shifts the preexisting conformational equilibrium to varying extents to achieve multidrug recognition. Meanwhile, the compound binding induces redistribution of ps–ns dynamics to the allosteric sites, which entropically favors the high-affinity recognition. Furthermore, the reciprocal compound/promoter binding by LmrR is achieved by the incompatible conformational ensembles between the compound- and promoter-bound states. Collectively, the data show how LmrR can dynamically exert its functions through promiscuous multi-target interactions, in a manner that cannot be understood by a static structural view.

The acquisition of multidrug resistance (MDR) by pathogenic bacteria is a major threat in the treatment of infectious diseases. Up-regulation of the expression of multidrug transporters that expel toxic compounds from cells is a strategy commonly employed by bacteria with MDR ability^{1–3}. The expression of multidrug transporters is strictly regulated by transcriptional activators and/or repressors, which tend to have the ability to bind multiple toxic compounds⁴. In addition, the toxic compounds that are recognized by the multidrug transcriptional regulator and excreted by the transporters are often the same. Thus, drug excretion systems consisting of a set of multidrug transcriptional regulators and transporters efficiently upregulates the expression of the required multidrug transporters in response to toxic compounds. Similar systems are also well-documented in eukaryotes, especially in human cancers^{5,6}.

A Gram-positive bacterium, *Lactococcus lactis*, exhibits MDR when exposed to increasing concentrations of structurally unrelated toxic compounds, such as Hoechst 33342 (H33342), daunomycin, ethidium, and rhodamine 6G (Rho6G)^{7,8} (Fig. 1a). The MDR phenotype is induced by the overexpression of a heterodimeric multidrug transporter, LmrCD⁹. The expression of LmrCD is regulated by a multidrug transcriptional repressor, LmrR, which is encoded in the same gene cluster as the *lmrCD* gene¹⁰. LmrR is a homodimeric protein that belongs to the PadR-like family of multidrug transcriptional regulators^{4,11}. In the absence of the compound, LmrR binds to the promoter regions of the *lmrCD* genes to repress their transcription (Fig. 1b). When the cells are exposed to the toxic compounds, LmrR is released from the promoter regions to induce membrane expression of the transporter¹². LmrR has been shown to bind the aforementioned compounds with relatively high affinities¹³, thus, is a major sensory molecule that controls multidrug resistance in *L. lactis*.

The structures of LmrR in the *apo* state and in complexes with H33342 or daunomycin have been determined¹³. The LmrR dimer contains winged helix–turn–helix (wHTH) DNA-binding motif on the side of the molecule (Fig. 1c), which is thought to fit into successive DNA major grooves with the DNA-recognition helix, α3. The α4 helix, together with the α1 helix, forms a hydrophobic pore at the dimeric center to form the compound binding site. The compound binding has been proposed to change the orientation of the C-terminal α4 helix relative to the wHTH domain (Fig. 1d). In the *apo* and H33342-bound structures, the α4 helix is in an *upper* orientation. In contrast, the α4 helix lies more horizontally and adopts *lower* orientations in the daunomycin-bound structures. Thus, the common structural change upon the compound binding, which leads to the release of LmrR from the promoter regions, has not been identified. Nevertheless, since each of the three X-ray structures of LmrR are derived from different crystal forms, it is not possible to determine whether the different orientations are induced

Figure 1 | Substrate, regulatory mechanism, and structural features of LmrR. (a), Chemical structures of compounds that bind to LmrR. (b), Schematic representation of gene regulation by LmrR. (c), Ribbon diagrams of LmrR in complex with daunomycin. The compound (green sticks) binds to the pore at the dimeric center. (d), Different orientations of the C-terminal $\alpha 4$ helix relative to the wHTH motif. A superposition of the *apo* (cyan and light green), H33342-bound (blue), and daunomycin-bound (orange and red) LmrR subunit structures is shown. Inset: Close-up view of the hinge region. Ile-62 sidechain is shown as sticks while Ile-84 and Asn-88 are shown in surface representations.

by compound binding or simply reflect differences in crystal packing¹³. The $\alpha 4$ -helix orientations are correlated with the relative orientation between the DNA-binding $\alpha 3$ helices of LmrR. The distance between the $\alpha 3$ helices decreases with the *lower* $\alpha 4$ -helix orientations than in the *upper* orientations¹³. However, none of the LmrR structures determined thus far is compatible with binding to B-form DNA. Therefore, the structural analysis of LmrR in the promoter-bound state as well as in the compound-bound states in solution, without any distortion caused by experimental conditions, is required, to reveal the molecular mechanism by which LmrR binds to various structurally unrelated compounds and is released from the promoter region to show the MDR phenotype.

Results

Dynamics of LmrR in the *apo* state. To characterize the dynamic nature of LmrR, we subjected the protein to solution NMR measurements. The backbone dynamics of *apo* LmrR were analyzed by the longitudinal and transverse ^{15}N relaxation rates (R_1 and R_2 , respectively), as well as the (^1H) - ^{15}N heteronuclear nuclear Overhauser effects (NOEs). The mainchain ^{15}N relaxation

analyses clearly indicated the existence of slow μs -ms chemical exchange at the compound-binding site, which is reflected in the large R_2/R_1 values observed for the residues in the $\alpha 1$ and $\alpha 4$ helices (Supplemental Fig. 1a). Since the ^{15}N R_2 was insensitive in Carr-Purcell-Meiboom-Gill (CPMG) experiments up to 1 kHz, the time scale of the dynamics in compound-binding site is much faster than the ms range. In addition, the low (^1H) - ^{15}N heteronuclear NOE values indicated that part of the $\alpha 4$ helix exhibits substantial rapid internal dynamics on a ps-ns timescale (Supplemental Fig. 1b). Taken together, the compound-binding site of LmrR, especially the C-terminal $\alpha 4$ helix, displays intensive ps- μs dynamics in the *apo* state.

In the crystal structures of LmrR, a significant variation was observed in the $\alpha 4$ helix orientations, which might reflect its accessible conformational landscape (Fig. 1d). The differences in the $\alpha 4$ -helix orientation are reflected in the different rotameric states of the residues in the hinge region that connects the N-terminus of the $\alpha 4$ helix to the wHTH domain. In particular, the χ_2 angle of Ile-62 adopts the *gauche*- and *trans* rotameric states when the $\alpha 4$ helix is in the *upper* and *lower* orientations, respectively (Fig. 1d, inset). In

the *upper* α 4-helix orientations, Ile-62 χ 2 is in the *gauche*- rotamer and the δ 1 methyl moiety is accommodated in a small pocket, formed by Ile-84 and Asn-88 of the α 4 helix. Conversely, in the *lower* orientations, the χ 2 angle of Ile-62 is in the *trans* rotamer and the Ile-62 δ 1 methyl moiety is rotated away from the α 4 helix, due to the steric hindrance. Note that we assumed an exchange between not single, but multiple *upper* and *lower* orientations, based on the X-ray structures of LmrR (Fig. 1d), which demonstrated that *upper* and *lower* α 4-helix orientations with different tilt angles exist for each rotameric state. Since the Ile χ 2 angle is correlated with the ^{13}C chemical shift of the δ 1 position¹⁴, the ^{13}C chemical shift and line shape of the Ile-62 δ 1 resonance would reflect the population of the *upper* and *lower* α 4-helix conformations at each state. In the ^1H - ^{13}C HMQC spectrum of *apo* LmrR, the Ile-62 δ 1 signal is broadened in the ^{13}C dimension as compared to the others (Fig. 2a). According to the chemical shift value, the Ile-62 χ 2 angle has a 1:1 population between the *gauche*- and *trans* rotamers in *apo* LmrR. Furthermore, the Ile-62 δ 1 methyl showed a substantially low order parameter (S^2 ; 0.17 ± 0.01 , Fig. 2b), as compared to the others, except Ile-115 in C-terminal disordered region. These results indicated that the Ile-62 χ 2 angle in the *apo* state undergoes rotameric exchange, reflecting an equally populated conformational equilibrium of the α 4 helix among the *upper* and *lower* orientations.

To further assess the conformational equilibrium observed in the *apo* state, we analyzed the temperature dependence of the methyl resonances from 281 K to 303 K. The ^{13}C chemical shift of the Ile-62 δ 1 resonance in the *apo* state was significantly shifted to high-field positions at lower temperatures (Fig. 2c). The ^{13}C chemical shift difference between 281 K and 303 K was 0.78 ppm. This indicated that the population of the *gauche*- χ 2 rotameric state of Ile-62 is increased from 50% to 65% by the temperature reduction from 303 K to 281 K, reflecting the preference for the *upper* α 4-helix conformations at low temperature (Fig. 2d). As discussed above, Ile-62 χ 2 in the *upper* α 4-helix conformation adopted the *gauche*-rotamer and the δ 1 methyl moiety of Ile-62 in the *gauche*- rotamer is accommodated in a small pocket, formed by Ile-84 and Asn-88 of the α 4 helix, in the X-ray structure of LmrR (Fig. 1d). In agreement with this observation, the *gauche*- rotameric state is calculated to be -4.5 kcal mol⁻¹ more enthalpically favorable than the *trans* rotameric state, according to the average slope of the van 't Hoff plot of the Ile-62 χ 2 rotameric states (Fig. 2d). It should be noted that the fit of the van 't Hoff's equation appears to be non-linear, although the non-linearity seems to be within the experimental errors derived from the acquisition resolution of the indirect ^{13}C dimension. The non-linear characteristic might suggest that the heat capacity is changing within the temperature range tested. It should be noted that the dynamics of methyl groups are known to contribute to the heat capacity of a protein, through its local conformational entropy¹⁵. Fig. 2e shows the temperature-dependent changes in the rotameric populations of the Ile χ 2, Leu χ 2, Met χ 3, and Val χ 1 angles. The residues that exhibited substantial temperature-dependent population changes upon temperature reduction were distributed around the α 4 helix, further supporting the presence of the conformational equilibrium of the α 4 helix in the *apo* state of LmrR.

LmrR conformation in compound-bound state. To characterize the conformational changes associated with compound binding, four known compounds, H33342, daunomycin, ethidium, and Rho6G, which have different sizes and shapes, were titrated to LmrR. SPR analyses indicated that these compounds bind to LmrR with various affinities, with dissociation constants (K_D) values ranging from nM to μM (Supplemental Fig. 2a). The K_D values for H33342 and daunomycin were consistent with those previously reported¹³. The chemical shift perturbations (CSPs) for each amide backbone resonance of LmrR revealed that LmrR engages the compounds with its compound-binding pore (Fig. 3). The amide

CSPs induced by compound ligation were mostly converged in the middle of the compound binding site, and thus they directly reflected the proximity of these amides to the compound in the bound states. Therefore, the amide CSPs would vary, depending on the chemical structures of the compounds and their respective binding modes. As expected from the X-ray crystal structures of LmrR, all compounds tested showed 1:1 binding stoichiometry.

Interestingly, the binding of different compounds induced similar CSPs to the Ile δ 1 signals (Fig. 4a). In addition, the CSPs induced by the binding of H33342 to sites remote from the compound-binding interface, including those from the N- and C-termini of α 1 and α 4 helices, correlated well with the CSPs induced by the binding of other compounds (Fig. 4b). Since the methyl groups of Ile δ 1 as well as those depicted in Fig. 4b are all far away from the compound binding site, and each chemical shift is a sensitive indicator of its local conformational and dynamical states^{14,16–20}, the correlations between the CSPs from the remote sites shown in Fig. 4b reflect the common global conformational changes that are induced by compound ligation. The observation is a stark contrast to the X-ray structures of LmrR, which showed opposite structural changes upon binding to H33342 and daunomycin. As mentioned above, the orientations of the α 4 helix are coupled to the Ile-62 ^{13}C chemical shift of the δ 1 position¹⁴. Thus, the substantial high-field shift of the Ile-62 δ 1 resonance in the ^{13}C dimension, upon compound binding, indicates an elevated proportion of the *upper* orientations in the α 4-helix conformational ensemble. The high-field Ile-62 δ 1 ^{13}C chemical shift changes observed upon compound ligation correspond to 6–12% increase in the *gauche*- rotamer of the Ile-62 χ 2 angle, which prefers *upper* α 4 helix orientations. It should be noted that the position of the Ile-62 δ 1 is always more than 4 Å away from the compound-binding site, and thus its ^{13}C chemical shift might not be directly affected by compound binding. It should be also noted that CSPs induced to amide resonances in Fig. 3 would vary, depending on the chemical structures of the compounds and their respective binding modes. In contrast, the Ile and remote methyl CSPs have to be comparable to those induced by the other compounds, as they reflect shared structural change.

LmrR dynamics in compound bound-state. To determine the extent of variation of the α 4-helix conformations in *apo* LmrR, as well as in the compound-bound states, we prepared 65 mutants of the residues in the α 4 helix, and those located at the interface with the α 4 helix (Supplemental Fig. 3a). Each mutation introduced a perturbation of the conformational equilibrium of the α 4 helix, and the degree of perturbation was monitored by the ^{13}C chemical shift of the Ile-62 δ 1 resonances (Supplemental Fig. 3b). The ^{13}C chemical shift changes in the Ile-62 δ 1 resonance, as compared to wild type (WT) LmrR, upon the introduction of each mutation are shown in Fig. 5a. The maximum ^{13}C chemical shift change was 0.85 ppm, which is comparable to that induced by temperature changes (Fig. 2c). Thus, the mutants sampled the conformational equilibrium that would reasonably be accessible for WT LmrR.

The ^{13}C chemical shifts of the Ile-62 δ 1 resonance in the various mutants in the *apo* form, as well as in the compound-bound forms, are shown in Fig. 5b. The Ile-62 δ 1 resonance showed a wide distribution of ^{13}C chemical shifts, ranging from 11–12.5 ppm, reflecting the shallow energetic potential landscape and the significant variety in the preexisting conformational states in *apo* LmrR. Upon compound binding, the distribution of the ^{13}C chemical shifts of the Ile-62 δ 1 resonance was shifted to high-field (*i.e.* low-frequency) positions to a different extent for each compound, and the range of the chemical shift variations became smaller. Interestingly, the chemical shift variation observed in the *apo* state includes a substantial part of chemical shift distribution observed in the compound-bound states. This indicated that compound ligation increases the populations of the *upper* α 4-helix conformations, among the preexisting conformational ensembles in the *apo* state.

Figure 2 | Conformational equilibrium in *apo* LmrR. (a), The Ile $\delta 1$ region of the ^1H - ^{13}C HMQC spectra of LmrR in the *apo* state. (b), Methyl S^2 values of Ile $\delta 1$. Error bars correspond to standard deviation (SD) of fitting errors. (c), Temperature dependence of the Ile $\delta 1$ resonances of *apo* LmrR. (d), The van 't Hoff plot for the Ile-62 $\chi 2$ angle rotational equilibrium in the *apo* state. The error bars correspond to the acquisition resolution of indirect ^{13}C dimension. e, Temperature-dependent population change in Ile $\chi 2$, Leu $\chi 2$, Met $\chi 3$, and Val $\chi 1$ rotameric states between 281K and 303K. Right: the methyl moieties with more than 10% or 3% rotameric population shift in response to the temperature variation are highlighted in red and yellow, respectively. The methyl moieties that did not show more than 3% rotameric population shift were depicted by small blue spheres.

Figure 3 | CSPs of mainchain amide resonances of LmrR upon binding to compounds. H33342, daunomycin, ethidium, and Rho6G were added at the indicated concentrations. (a), Plot of the magnitudes of the normalized chemical shift change for each residue. The resonances that were only observable in the compound-bound states are indicated with asterisks. (b), Mapping of significantly perturbed (>0.05 ppm) residues on the ribbon representation of LmrR. Residues that were not observed in each bound state are shown in black.

To understand the thermodynamic nature of the LmrR-compound interaction, isothermal titration calorimetry (ITC) analyses were performed. Within the binding free energy of the LmrR-compound interactions, the enthalpic contributions, which reflect the formation of spatially aligned interactions, are small or even unfavorable (Supplemental Fig. 2b and c). While the major entropic term favoring association would be the desolvation from the hydrophobic compound-binding pore of LmrR, changes in the protein conformational entropy would also account for the ligand binding affinity²¹. To determine the contribution of the protein conformational

Figure 5 | Conformational equilibrium of the $\alpha 4$ helix revealed by allosteric mutations. (a), The ^{13}C chemical shift change of the Ile-62 $\delta 1$ resonance in each mutant, relative to WT LmrR in the *apo* state. (b), The box and whisker plot of the ^{13}C chemical shift of the Ile-62 $\delta 1$ resonance in various mutants in the *apo* state as well as in complexes with compounds. The red horizontal line indicates the ^{13}C chemical shift of the Ile-62 $\delta 1$ resonance of WT LmrR in each state.

entropy to the LmrR-compound binding, we employed ^1H spin-based relaxation violated triple-quantum (3Q) coherence transfer NMR spectroscopies, to measure the changes in S^2 (ΔS^2) of the methyl groups upon compound binding^{22,23}. Since S^2 is a measure of the amplitude of internal dynamics, it is related to the conformational entropy^{24–35}. Compound binding to LmrR resulted in a notable increase in the amplitude of ps–ns dynamics throughout the entire protein, except for a few methyl moieties in the compound binding site (Fig. 6). The residues that showed increased ps–ns dynamics are concentrated at the interface between the compound-binding and DNA-binding domains (upper left and lower right corner in the structures shown in Fig. 6), which is allosteric to the compound-

binding site and exhibited small amplitude of ps–ns dynamics in the *apo* state (Supplemental Fig. 5). Thus, the compound binding induces the redistribution of the ps–ns dynamics in LmrR, thereby favorably contributing to the binding by increasing the conformational entropy.

Reciprocal compound/promoter binding. LmrR shows reciprocal compound- and promoter-DNA-binding properties. To gain structural insights into the reciprocal interactions, we subjected the LmrR–promoter complex to SPR and solution NMR studies. It has been suggested that LmrR interacts with the promoter/operator region of the *lmrCD* gene, including an imperfect inverted repeat

Figure 6 | Enhancement of ps-ns motions in allosteric sites upon compound binding. Left panels show ΔS^2 values for each methyl resonance upon binding to (a), H333342, (b), daunomycin, (c), ethidium, and (d), Rho6G. The right panel displays the color-coded mapping of the methyl moieties that showed substantial ΔS^2 values upon binding to each compound. Error bars correspond to SD of fitting errors.

(IR) with a PadR consensus. Thus, we used the 33-bp promoter DNA fragment, containing the IR sequence, for the analyses (Supplemental Fig. 6a; hereafter, we refer to this as the *lmrCD* oligo). The SPR analyses indicated that the *lmrCD* oligo showed μM affinity for LmrR (Supplemental Fig. 6b) and was dissociated from LmrR in the presence of the compounds (Supplemental Fig. 6c). Titration of the *lmrCD* oligo to LmrR induced a low-field shift in the

Ile-62 $\delta 1$ ^{13}C chemical shift, which indicated that the conformational equilibrium of the $\alpha 4$ helix was shifted to have higher proportion of the lower orientations (Fig. 7a). In addition, the Ile $\delta 1$ CSPs induced by the *lmrCD* oligo were anti-correlated with those induced by the compounds (Fig. 7b). Thus, the compounds and the promoter DNA prefer distinct $\alpha 4$ -helix conformational ensembles present in LmrR, and provide the structural basis for the reciprocal binding.

Figure 7 | NMR analyses of binding of promoter DNA oligo to LmrR. (a), The Ile $\delta 1$ region of the ^1H - ^{13}C HMQC spectrum of LmrR in the *apo* state (black) was overlaid with that of the *lmrCD* oligo-bound state (red) (b), The pairwise correlation between CSPs induced by daunomycin (left) and ethidium (right) against CSPs induced by the *lmrCD* oligo for each Ile $\delta 1$ resonance.

Discussion

Our structural and dynamical analyses of LmrR in the *apo* state revealed intensive ps- μs dynamics in the compound-binding site. LmrR adopts multiple $\alpha 4$ helix orientations, which are largely classified into the *upper* and *lower* conformations, and each of these conformations should have certain variations in their tilt angles (Fig. 1d). The *upper* and *lower* conformations are associated with *gauche*- and *trans* rotamers in Ile-62 $\chi 2$ angle, respectively. As discussed above, the *gauche*- rotamer is enthalpically preferred in the *upper* $\alpha 4$ -helix orientations, as it has additional contact between Ile-62 $\delta 1$ methyl and the $\alpha 4$ helix. The smallest ^{13}C chemical shift value of the Ile-62 $\delta 1$ methyl moiety for the H33342 complexes corresponds to 74% of rotameric state in the *gauche*- rotamer (Fig. 5b). Thus, the Ile-62 $\chi 2$ angle would, at least in its majority, be in the *gauche*- rotamer when $\alpha 4$ -helix is in *upper* orientations. On the other hand, the *lower* orientation forces the Ile-62 $\chi 2$ angle to take *trans* rotamer due to steric hindrance. Thus, the average population and rate of exchange between the *upper* and *lower* conformations are reflected in the ^{13}C chemical shift and line shape of the Ile-62 $\delta 1$ resonance. In the *apo* state, the *upper* and *lower* conformations are almost equally distributed, indicating that those conformers on average are energetically degenerate (Figs. 2d and 8a; top). Theoretically, an energetically degenerate system is the most sensitive to a perturbation that shifts the conformational equilibrium³⁶. Thus, *apo* LmrR appears to be optimally suited for sensing and responding to a variety of compounds, by shifting the conformational ensembles to those that differ from *apo* LmrR. There should be a small but appreciable barrier between the *upper* and *lower* $\alpha 4$ helix conformations, judging from a broader ^{13}C line width in the Ile-62 $\delta 1$ signal (Fig. 2a), which would not be observed if no activation barrier existed between conformations. Considering the facts that ^{15}N R_2 was insensitive in CPMG experiments up to 1 kHz and that the Ile-62 $\delta 1$ gives a single line of resonance, the exchange rate between the conformations should be faster than 10^3 s^{-1} and the apparent activation energy would be smaller than 13 kcal mol^{-1} , according to the Arrhenius equation.

The compound binding shifts the conformational ensemble of the $\alpha 4$ helix observed in *apo* LmrR to a higher proportion of the *upper* conformers, but to a different extent for each compound (Figs. 5b and 8a; middle). Thus, there are common structural changes, which have not been identified by the former structural study of LmrR. The multidrug recognition mechanism is somewhat similar to the multi-protein recognition by ubiquitin via a conformational selection mechanism³⁷, in which the *bound* conformations of ubiquitin are already present in the free state. However, in stark contrast to the

multi-protein recognition by ubiquitin, LmrR possesses only one compound-binding pore, whereas ubiquitin has distinct binding sites on the molecule for different interaction partners. The ps- μs dynamics in the LmrR compound-binding site is not fully suppressed upon compound binding (Fig. 5b and Supplemental Fig. 4), and only limited numbers of the methyl moieties in the compound-binding site showed reduced ps-ns dynamics upon compound binding (Fig. 6). Thus, the loss of protein conformational entropy at the binding interface, which typically accompanies complex formation²¹, was limited in the LmrR-compound interactions.

Interestingly, the compound binding enhanced the ps-ns dynamics in the sites that are allosteric to the compound-binding interface (Fig. 6). The redistribution of the ps-ns dynamics would entropically favor the interactions between LmrR and the compounds. Although the major favorable entropic term associated with the compound binding arises from the desolvation effect, the redistribution of the fast internal dynamics in the allosteric sites would also positively contribute to the compound interaction. From the recently proposed relationship between measured methyl-group S^2 and conformational entropy³⁸, -0.5 to -1.5 kcal/mol of entropic energy gain were expected upon compound binding, which increases the binding affinity by 2- to 13-fold. Since LmrR is a sensory molecule that detects various toxic compounds, the high affinities toward the compounds are prerequisite to its function. In this sense, LmrR represents an elaborate system that is compatible with both high-affinity binding and multidrug recognition, via the redistribution of the ps-ns motions upon compound ligation.

In Fig. 8b, we show a schematic representation of the compound recognition by LmrR, compared to that of the TetR-family multidrug transcriptional repressors. The NMR analysis revealed that LmrR recognizes various structurally unrelated compounds by shifting the equilibrium among the conformational ensembles presented in the *apo* form (Fig. 8a and b; left). This recognition mode is quite different from the multidrug recognition by the TetR-family multidrug transcriptional repressors, which utilize multiple specific binding spots in a wide binding pocket to recognize multiple compounds (Fig. 8b; right). The difference is reflected in the thermodynamics of the compound recognition. While the binding of the compounds to LmrR is entropically favored, the compound binding to a TetR-family member, QacR, is enthalpically favored and entropically disfavored, which clearly indicate the specific bond formations that potentially limit the structure of the compound that can be accommodated by QacR³⁹. We should emphasize that the multidrug recognition mechanisms of QacR, as with other mechanisms proposed for other families of multidrug transcriptional regulators, rely on the

Figure 8 | Multidrug recognition and transcriptional regulation through differential shifting of the preexisting conformational equilibrium. (a), In the *apo* state, LmrR exists as a conformational ensemble with multiple $\alpha 4$ -helix orientations, in which the *upper* and *lower* conformations are almost equally represented (top). Compound ligation shifts the preexisting conformational equilibrium to various extents, to achieve multidrug recognition (middle). The reciprocal compound/promoter binding by LmrR is achieved by the incompatibility of the conformational ensembles (lower). (b), Comparison of the multidrug recognition by LmrR (left) with that by QacR (right). LmrR binds to multiple compounds using the same site without being locked into a specific conformer. In contrast, QacR possesses multiple specific binding spots in a wide binding pocket to recognize multiple compounds using different sites.

specific protein-drug interactions, and thus the number of the compounds accommodated by the mechanisms is limited. However, the multidrug recognition through a dynamic shift of conformational equilibrium does not rely on prerequisite bond formations, and thus, in principle, is able to accommodate almost unlimited number of compounds with planar aromatic structures that can fit into the

single drug binding pore and represents a multidrug binding mechanism, which does not fall into any category proposed thus far.

Lastly, the distinct conformational ensembles preferred by the promoter DNA and the compounds (Figs. 7 and 8a), which we found here, are fundamental to the reciprocal compound/promoter binding by LmrR. This would occur via structural coupling between the $\alpha 4$ -helix orientation and the distance between the $\alpha 3$ DNA-recognition helices. The compound binding increases the *upper* conformations of the $\alpha 4$ helix, causing an increase in the average distance between the $\alpha 3$ helices. In contrast, binding to the promoter DNA oligo induces the *lower* conformations of the $\alpha 4$ helix, and thus the shorter distance between the $\alpha 3$ helices would be expected. In the absence of the promoter-bound structure of LmrR, we cannot rule out the possibility of DNA distortion; however, the perturbation of the LmrR conformational ensemble upon binding to the promoter DNA is evident from the promoter-induced CSPs. Ile-62 is located in the hinge region of the $\alpha 4$ helix and it is reasonable that Ile-62 showed a substantial ^{13}C CSP. In addition, Ile-57, which is located in the $\alpha 3$ DNA binding helix and interacts directly with the Ile-62 sidechain, also changed its rotameric state from *gauche*- to *trans* when the conformation of the $\alpha 4$ helices was shifted from *lower* to *upper*. Considering the location of Ile-57 and its correlation to the conformation of the $\alpha 4$ helix, Ile-57, along with Ile-62, would form the structural core to transfer the $\alpha 4$ conformation to $\alpha 3$ DNA binding helix, which serves as a conformation switch that induces LmrR dissociation from the promoter upon compound ligation.

Methods

Preparation of LmrR. The DNA fragment (5'-GGCCATGGGCATGGCCGAAA-TTCGAAAGAGATGCTTCGTGCTCAGACCAATGTGATTCTGCTGAAT-GTCTGAAACAGGGTGATAACTACGTATATGGCATTATCAAAACAGGTG-AAAGAACGCGAGTAATGGCGAAATGGAAGTGAACGAAGCAACTCT-CTACACCATCTTCAAACGCCTGGAGAAAGATGGGATCATTAGCAGCTA-TTGGGGTGATGAATCTCAAGGTGGACGTGCAAGTACTATCGCTTGA-CGGAAATTGGCCATGAGAACATGCGGTTAGCCTTTGAATCGTGGTCAC-GTGTGACAGATCATTGAGAATCTGGAAGCGCAACAGAAA-TCCGAAGCGATCAAACCTCGAGTGA-3') encoding *L. lactis* LmrR, with optimized codon usage for *Escherichia coli* (*E. coli*) protein expression, was synthesized (Operon) and ligated into a pET28b vector (Novagen) at the *Nco I* and *Xho I* restriction sites. The resultant vector expresses LmrR with a C-terminal His6-tag. LmrR mutants were constructed by the QuikChange™ strategy (Agilent Technology). *E. coli* strain BL21(DE3) was transformed with the plasmid. Fresh colonies of the BL21 (DE3) harboring the LmrR plasmid were inoculated in 10 mL of LB medium containing 50 $\mu\text{g/mL}$ kanamycin and cultured at 37 °C for 4 hrs. The cells were collected by centrifugation and further inoculated into 1 L of kanamycin-M9 medium supplemented with 3 g/L d-glucose and 1 g/L $^{15}\text{NH}_4\text{Cl}$ as the sole carbon and nitrogen source, respectively. At an optical density at 600 nm wavelength (OD_{600}) of 0.8, 0.6 mM isopropyl- β -D-thiogalactopyranoside (IPTG) was added to induce LmrR expression. The induced culture was further incubated at 27 °C for 16 hours. For the expression of deuterated LmrR, D_2O -based M9 media supplemented with 3 g/L $[\text{H}_2\text{-}^{13}\text{C}_6]$ -D-glucose or $[\text{H}_2\text{-}^2]\text{-D-glucose}$ was used, depending on the experimental purposes. For selective $^{13}\text{CH}_3$ -labeling of the Ala, Ile (Ile- $\delta 1$), Leu/Val, and Met methyl groups, 50 mg/L of $[3\text{-}^{13}\text{C}, 2\text{-}^2\text{H}]$ L-alanine, 100 mg/L of $[\text{methyl-}^{13}\text{C}, 3,3\text{-}^2\text{H}_2]\text{-}\alpha$ -ketobutyric acid, 100 mg/L of $[3\text{-methyl-}^{13}\text{C}, 3,4,4,4\text{-}^2\text{H}_4]\text{-}\alpha$ -ketoisovaleric acid, and 50 mg/L of $[\text{methyl-}^{13}\text{C}]$ L-methionine were supplemented into the medium 30 min prior to the addition of IPTG. The cells were harvested by centrifugation and frozen at -80°C before purification.

The frozen pellets of LmrR-expressing cells were resuspended in lysis buffer consisting of 50 mM Tris-HCl (pH 8.0), 300 mM NaCl, and 10 mM imidazole, and the cells were disrupted by sonication. LmrR was purified from the supernatant of the cell lysate. The supernatant was applied to a 3 mL COSMOGEL® His-Accept column, equilibrated with the buffer, which is same as the lysis buffer. The column was washed with 40 mL of the equilibration buffer, and then LmrR was eluted with 20 mL of elution buffer, containing 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, and 300 mM imidazole. The eluate was concentrated by ultrafiltration, using an Amicon Ultra centrifugal filter unit (molecular weight cutoff 10 K; Millipore), and then passed through a 0.22 μm syringe filter for further purification by size exclusion chromatography (SEC). The sample was applied to a HiLoad Superdex 75 prep grade column (GE Healthcare), equilibrated with 50 mM sodium phosphate buffer (NaPi; pH 6.8) containing 300 mM NaCl. The elution fraction was collected, buffer-exchanged into NMR buffer containing 10 mM NaPi (pH 6.8) and 100 mM NaCl, and stored at -80°C until use.

NMR experiments. All experiments were performed on either Bruker Avance-600, -700, or -800 MHz spectrometers equipped with room temperature (700 MHz) or

cryogenic (600 and 800 MHz) triple resonance probes. All spectra were collected using 10 mM NaPi buffer (pH 6.8) containing 100 mM NaCl in either 90% H₂O/10% D₂O or 100% D₂O, depending on the experiments. The typical concentration of LmrR was 0.1–0.2 mM as a monomer. Unless otherwise noted, the experiments were performed at 298 K. Spectra were processed using TOPSPIN (Bruker Biospin) and analyzed with Sparky. The backbone assignments of LmrR were accomplished using standard TROSY triple-resonance experiments. The two-dimensional ¹H–¹⁵N HSQC spectrum of LmrR in the apo state showed good overall dispersion (Supplemental Fig. 7A); however, the backbone amide ¹H–¹⁵N cross-peaks could not be detected for residues 4 and 6–8 in the α1 helix and residues 96, 97, 105, and 106 in the α4 helix. The unobservable residues are all in the compound-binding site, and the intensities of the mainchain resonances were weak in the entire compound-binding site (Supplemental Fig. 7B). Assignments of the Ala, Ile, Leu, Met, and Val methyl resonances of LmrR were performed by combining mutational analysis, J-coupling-based triple resonance experiments ((H)CC(CO)NH, H(CCCO)NH, and HCCH-TOCSY experiments), and an analysis of the inter-methyl ¹H–¹H NOE network, based on the crystal structures. For the Leu and Val methyl resonances, stereospecific assignments were achieved by using [2-methyl-¹³C, 4,4,4-³H₃] acetolactate (NMR-Bio) as the precursor. The ¹H–¹³C HMQC spectra of LmrR with assignments are shown in Supplemental Fig. 7C.

The R₁ and R₂ relaxation rates and the (¹H)–¹⁵N heteronuclear NOEs of LmrR were measured using published ¹H-detected 2D NMR pulse sequences³⁹. The relaxation delays used were 50, 100, 200, 400, 800, 1200, and 1600 ms for R₁, and 17, 34, 51, 68, 85, 102, 119, and 136 ms for R₂ measurements. R₁ and R₂ values were determined by exponential fits, and their uncertainties were used as the standard errors of the fitted parameters. The steady-state heteronuclear (¹H)–¹⁵N heteronuclear NOEs experiments were performed using a symmetric proton irradiation scheme⁴⁰. The protein saturation period before the ¹⁵N excitation pulse and the total recycling delay were set to 4.0 s and 8.0 s, respectively, to ensure the maximal development of NOEs before acquisition and to allow complete relaxation of the system. Error estimates were calculated from two separate experiments.

The rotameric equilibria of the Ile γ₂, Leu γ₂, Met γ₃, and Val γ₁ angles were deduced from the Ile (δ₁), Leu, Met, and Val methyl ¹³C chemical shifts, respectively. The ¹³C chemical shifts of methyl signals are reportedly dependent on the sidechain rotamer, as revealed by theoretical and experimental analyses^{14,16–18}. The population of the *trans* rotameric state (*p_t*) for each residue was calculated according to the chemical shift values of the methyl ¹³C signals (δ_{obs}, ppm) using the equations (1–4) below:

$$^{13}\text{C}_\epsilon \text{ Met: } \delta_{\text{obs}} = 15.9 + 3.6 p_t \quad (1)^{16}$$

$$^{13}\text{C}_\delta \text{ Ile: } \delta_{\text{obs}} = 9.3 + 5.5 p_t \quad (2)^{14}$$

$$^{13}\text{C}_\delta \text{ Leu: } \delta_{\text{obs}}, \delta_1 - \delta_{\text{obs}}, \delta_2 = -5 + 10.0 p_t \quad (3)^{17}$$

$$^{13}\text{C}_\gamma \text{ Val: } \delta_{\text{obs}}, \gamma_1 - \delta_{\text{obs}}, \gamma_2 = 4.1 - 6.6 p_t \quad (4)^{18}$$

If the equation yielded a *p_t* value >1 or <0, then the *p_t* was fixed to 1 (all *trans*) or 0 (all *gauche*–), respectively.

To measure the order parameters of the methyl groups (*S*²_{axis}) in LmrR, we employed the ¹H spin-based relaxation violated coherence transfer NMR spectroscopies^{22,23}. For this purpose, we used samples in which the methyl groups of Ala, Ile, Leu, Met, and Val residues were ¹³CH₃-labeled, in an otherwise deuterated background. The intra-methyl ¹H–¹H dipolar cross-correlated relaxation rates η were obtained by fitting the ratios of the peak intensities measured in pairs of data sets (*i.e.* forbidden and allowed data) recorded as a function of relaxation time, *T*, to the following equation (5):^{22,23}.

$$\left| \frac{I_a}{I_b} \right| = C \frac{\eta \tanh(\sqrt{\eta^2 + \delta^2} T)}{\sqrt{\eta^2 + \delta^2} - \delta(\sqrt{\eta^2 + \delta^2} T)} \quad (5)$$

where *T* is the varied delay, δ is a parameter related to the density of the external protons around the methyl group, and *I_a* and *I_b* are the intensities of the forbidden and allowed coherences, respectively, with the delay *T*^{22,23}. The data sets were recorded using the following sets of relaxation delays *T*: 1, 2, 5, 7, 10, 15, 20, 30, and 40 ms at 298 K. The recovery delay was set to 1.5 s.

*S*²_{axis} values were calculated by the determined η value using the equation (6) below:

$$\eta = \frac{R_{2,H}^F - R_{2,H}^S}{2} \approx \frac{9}{10} [P_2(\cos \theta_{\text{axis,HH}})^2 S_{\text{axis}}^2 \gamma_H^4 \hbar^2 \tau_c / r_{\text{HH}}^6] \quad (6)$$

where τ_c is the rotational correlation time of LmrR, *R*^F_{2,H} and *R*^S_{2,H} are the relaxation rates of fast and slowly relaxing coherences, respectively, γ_H is the gyromagnetic ratio of the proton, and *r*_{HH} is the distance between pairs of methyl protons. The rotational correlation time was set to 20 ns, and was determined by TRAC analyses⁴¹.

The normalized chemical shift perturbation values (Δδ) were calculated as follows:

$$\Delta\delta = \sqrt{(\Delta\delta H)^2 + (\Delta\delta N/5)^2} \quad (7)$$

Surface plasmon resonance (SPR) spectroscopy. All SPR experiments were performed using a BIACORE3000 system (GE Healthcare) at 25°C. LmrR was immobilized to an NTA sensor chip. The binding assay was performed in HBS-P running buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 50 μM EDTA, 0.005% surfactant P-20) at flow rate of 40 μL/min, using serial dilutions of compounds. Specific binding responses to compounds were obtained by subtracting the response from a flow cell that was not coated with LmrR. For the binding of daunomycin, ethidium, and Rho6G, the equilibrium resonance (R_{eq}) from the SPR sensorgrams as function of the compound concentration was plotted and non-linearly fitted to a one-site binding isotherm was used to obtain the *K_D* values. The binding constant for H33342 was determined by a kinetic analysis assuming 1:1 Langmuir binding. Analyses of the sensorgrams were performed with the BIA-evaluation Software 4.1.

ITC experiments. Calorimetric titrations of LmrR with compounds were performed with a VP-ITC microcalorimeter (MicroCal) at 25°C, using the same buffer as in the NMR experiments. Protein samples were extensively dialyzed against the buffer before the experiments. The sample cell was filled with a 5–50 μM solution of protein as monomer, and the injection syringe contained 100 μM of H33342, 100 μM of daunomycin, 500 μM of ethidium, or 500 μM of Rho6G. After a preliminary 3 μL injection, 24 subsequent 10 μL injections were performed. Heats were normalized by subtracting those without protein at each titration point to eliminate the effect of dilution. The data were fitted using the sequential binding site model embedded in Origin 7.0 (MicroCal).

- Ma, D., Cook, D. N., Hearst, J. E. & Nikaido, H. Efflux pumps and drug resistance in Gram-negative bacteria. *Trends in Microbiology* **2**, 489–493 (1994).
- Saier, M. H., Jr. *et al.* Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. *Faseb j* **12**, 265–74 (1998).
- van Veen, H. W. & Konings, W. N. Structure and function of multidrug transporters. *Adv Exp Med Biol* **456**, 145–58 (1998).
- Schumacher, M. A. & Brennan, R. G. Structural mechanisms of multidrug recognition and regulation by bacterial multidrug transcription factors. *Mol Microbiol* **45**, 885–893 (2002).
- Geick, A., Eichelbaum, M. & Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. *J Biol Chem* **276**, 14581–7 (2001).
- Riordan, J. R. *et al.* Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. *Nature* **316**, 817–9 (1985).
- Bolhuis, H. *et al.* Proton motive force-driven and ATP-dependent drug extrusion systems in multidrug-resistant *Lactococcus lactis*. *J Bacteriol* **176**, 6957–64 (1994).
- Lubelski, J., Mazurkiewicz, P., van Merkerk, R., Konings, W. N. & Driessen, A. J. ydaG and ydbA of *Lactococcus lactis* encode a heterodimeric ATP-binding cassette-type multidrug transporter. *J Biol Chem* **279**, 34449–55 (2004).
- Lubelski, J. *et al.* LmrCD is a major multidrug resistance transporter in *Lactococcus lactis*. *Mol Microbiol* **61**, 771–81 (2006).
- Agustiandari, H., Lubelski, J., van den Berg van Saparoea, H. B., Kuipers, O. P. & Driessen, A. J. LmrR is a transcriptional repressor of expression of the multidrug ABC transporter LmrCD in *Lactococcus lactis*. *J Bacteriol* **190**, 759–63 (2008).
- Wade, H. MD recognition by MDR gene regulators. *Curr Opin Struct Biol* **20**, 489–496 (2010).
- Agustiandari, H., Peeters, E., de Wit, J. G., Charlier, D. & Driessen, A. J. LmrR-mediated gene regulation of multidrug resistance in *Lactococcus lactis*. *Microbiology* **157**, 1519–30 (2011).
- Madoori, P. K., Agustiandari, H., Driessen, A. J. & Thunnissen, A. M. Structure of the transcriptional regulator LmrR and its mechanism of multidrug recognition. *Embo j* **28**, 156–66 (2009).
- Hansen, D. F., Neudecker, P. & Kay, L. E. Determination of Isoleucine Side-Chain Conformations in Ground and Excited States of Proteins from Chemical Shifts. *J Am Chem Soc* **132**, 7589–7591 (2010).
- Sabo, T. M. *et al.* Thermal coefficients of the methyl groups within ubiquitin. *Protein Sci* **21**, 562–570 (2012).
- Butterfoss, G. *et al.* Conformational dependence of ¹³C shielding and coupling constants for methionine methyl groups. *J Biomol NMR* **48**, 31–47 (2010).
- Hansen, D. F., Neudecker, P., Vallurupalli, P., Mulder, F. A. A. & Kay, L. E. Determination of Leu Side-Chain Conformations in Excited Protein States by NMR Relaxation Dispersion. *J Am Chem Soc* **132**, 42–43 (2009).
- London, R. E., Wingad, B. D. & Mueller, G. A. Dependence of Amino Acid Side Chain ¹³C Shifts on Dihedral Angle: Application to Conformational Analysis. *J Am Chem Soc* **130**, 11097–11105 (2008).
- Kofuku, Y. *et al.* Efficacy of the β₂-adrenergic receptor is determined by conformational equilibrium in the transmembrane region. *Nat Commun* **3**, 1045 (2012).
- Imai, S., Osawa, M., Takeuchi, K. & Shimada, I. Structural basis underlying the dual gate properties of KcsA. *Proc Natl Acad Sci* **107**, 6216–21 (2010).
- Brady, G. P. & Sharp, K. A. Entropy in protein folding and in protein–protein interactions. *Curr Opin Struct Biol* **7**, 215–221 (1997).

22. Sun, H., Kay, L. E. & Tugarinov, V. An Optimized Relaxation-Based Coherence Transfer NMR Experiment for the Measurement of Side-Chain Order in Methyl-Protonated, Highly Deuterated Proteins. *J Phys Chem B* **115**, 14878–14884 (2011).
23. Tugarinov, V., Sprangers, R. & Kay, L. E. Probing Side-Chain Dynamics in the Proteasome by Relaxation Violated Coherence Transfer NMR Spectroscopy. *J Am Chem Soc* **129**, 1743–1750 (2007).
24. Akke, M. Conformational dynamics and thermodynamics of protein-ligand binding studied by NMR relaxation. *Biochem Soc Trans* **40**, 419–23 (2012).
25. Akke, M., Brueschweiler, R. & Palmer, A. G. NMR order parameters and free energy: an analytical approach and its application to cooperative calcium(2+) binding by calbindin D9k. *J Am Chem Soc* **115**, 9832–9833 (1993).
26. Yang, D. & Kay, L. E. Contributions to Conformational Entropy Arising from Bond Vector Fluctuations Measured from NMR-Derived Order Parameters: Application to Protein Folding. *J Mol Biol* **263**, 369–382 (1996).
27. Li, Z., Raychaudhuri, S. & Wand, A. J. Insights into the local residual entropy of proteins provided by NMR relaxation. *Protein Sci* **5**, 2647–2650 (1996).
28. Marlow, M. S., Dogan, J., Frederick, K. K., Valentine, K. G. & Wand, A. J. The role of conformational entropy in molecular recognition by calmodulin. *Nat Chem Biol* **6**, 352–8 (2010).
29. Frederick, K. K., Marlow, M. S., Valentine, K. G. & Wand, A. J. Conformational entropy in molecular recognition by proteins. *Nature* **448**, 325–9 (2007).
30. Tzeng, S. R. & Kalodimos, C. G. Protein activity regulation by conformational entropy. *Nature* **488**, 236–40 (2012).
31. Kalodimos, C. G. NMR reveals novel mechanisms of protein activity regulation. *Protein Sci* **20**, 773–82 (2011).
32. Tzeng, S. R. & Kalodimos, C. G. Dynamic activation of an allosteric regulatory protein. *Nature* **462**, 368–72 (2009).
33. Popovych, N., Sun, S., Ebright, R. H. & Kalodimos, C. G. Dynamically driven protein allostery. *Nat Struct Mol Biol* **13**, 831–8 (2006).
34. Sapienza, P. J. & Lee, A. L. Using NMR to study fast dynamics in proteins: methods and applications. *Curr Opin Pharm* **10**, 723–730 (2010).
35. Petit, C. M., Zhang, J., Sapienza, P. J., Fuentes, E. J. & Lee, A. L. Hidden dynamic allostery in a PDZ domain. *Proc Natl Acad Sci* **106**, 18249–54 (2009).
36. Vallee-Belisle, A., Ricci, F. & Plaxco, K. W. Thermodynamic basis for the optimization of binding-induced biomolecular switches and structure-switching biosensors. *Proc Natl Acad Sci* **106**, 13802–7 (2009).
37. Lange, O. F. *et al.* Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. *Science* **320**, 1471–5 (2008).
38. Kasinath, V., Sharp, K. A. & Wand, A. J. Microscopic insights into the NMR relaxation-based protein conformational entropy meter. *J Am Chem Soc* **135**, 15092–100 (2013).
39. Brooks, B. E., Piro, K. M. & Brennan, R. G. Multidrug-Binding Transcription Factor QacR Binds the Bivalent Aromatic Diamidines DB75 and DB359 in Multiple Positions. *J Am Chem Soc* **129**, 8389–8395 (2007).
40. Ferrage, F., Cowburn, D. & Ghose, R. Accurate Sampling of High-Frequency Motions in Proteins by Steady-State ^{15}N – $\{^1\text{H}\}$ Nuclear Overhauser Effect Measurements in the Presence of Cross-Correlated Relaxation. *J Am Chem Soc* **131**, 6048–6049 (2009).
41. Lee, D., Hilty, C., Wider, G. & Wüthrich, K. Effective rotational correlation times of proteins from NMR relaxation interference. *J Magn Reson* **178**, 72–6 (2006).

Acknowledgments

This work was supported by a grant from the Japan New Energy and Industrial Technology Development Organization (NEDO) and the Ministry of Economy, Trade, and Industry (METI; to I.S.). Funding was also provided by Grants-in-Aid for Scientific Research (24370048 and 25121743 to K. T.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Society for the Promotion of Science (JSPS) and by JST, PREST (to K.T.).

Author contributions

K.T., Y.T., H.T. and I.S. conceived the project. K.T. and I.M. performed the experiments. K.T., Y.T., H.T. and I.S. wrote the manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Takeuchi, K., Tokunaga, Y., Imai, M., Takahashi, H. & Shimada, I. Dynamic multidrug recognition by multidrug transcriptional repressor LmrR. *Sci. Rep.* **4**, 6922; DOI:10.1038/srep06922 (2014).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>